Theravance Biopharma, Inc. Annual Operating Income (Loss) in USD from 2012 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Theravance Biopharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2012 to 2023.
  • Theravance Biopharma, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$10.8M, a 23.7% decline year-over-year.
  • Theravance Biopharma, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$44M, a 34.6% increase year-over-year.
  • Theravance Biopharma, Inc. annual Operating Income (Loss) for 2023 was -$56M, a 39.1% increase from 2022.
  • Theravance Biopharma, Inc. annual Operating Income (Loss) for 2022 was -$92M, a 64.3% increase from 2021.
  • Theravance Biopharma, Inc. annual Operating Income (Loss) for 2021 was -$258M, a 13.4% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$56M +$35.9M +39.1% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-01
2022 -$92M +$166M +64.3% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-01
2021 -$258M +$39.8M +13.4% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-01
2020 -$298M -$45.7M -18.1% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-01
2019 -$252M -$13.2M -5.51% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 -$239M +$21.4M +8.22% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-26
2017 -$260M -$79.7M -44.1% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-27
2016 -$180M +$1.43M +0.79% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 -$182M +$50.6M +21.8% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-28
2014 -$233M -$76.3M -48.8% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-01
2013 -$156M -$147M -1532% Jan 1, 2013 Dec 31, 2013 10-K 2016-03-11
2012 -$9.58M Jan 1, 2012 Dec 31, 2012 10-K 2015-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.